Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback